Glycosphingolipid degradation and animal models of GM2-gangliosidoses

Journal of Inherited Metabolic Disease

Volumn 21, Issue 5, 1998, Pages 548-563

  Kolter, T ^a   Sandhoff, K ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA N ACETYLHEXOSAMINIDASE; BETA N ACETYLHEXOSAMINIDASE A; BETA N ACETYLHEXOSAMINIDASE B; GANGLIOSIDE GM2; GLYCOSPHINGOLIPID; LYSOSOME ENZYME; MEMBRANE LIPID; MIGLUSTAT; SIALIDASE; SPHINGOLIPID ACTIVATOR PROTEIN;

CONFERENCE PAPER; DISEASE COURSE; DISEASE SEVERITY; ENDOSOME; ENZYME REPLACEMENT; EUKARYOTIC CELL; GENE THERAPY; GM2 GANGLIOSIDOSIS; HUMAN; KNOCKOUT MOUSE; LIPID METABOLISM; LIPIDOSIS; LYSOSOME; MUCOPOLYSACCHARIDOSIS; NONHUMAN; ORGAN TRANSPLANTATION; PATHOGENESIS; PHENOTYPE; SANDHOFF DISEASE; TAY SACHS DISEASE;

ANIMALS; DISEASE MODELS, ANIMAL; GLYCOSPHINGOLIPIDS; HUMANS; MICE; MICE, MUTANT STRAINS; SANDHOFF DISEASE; TAY-SACHS DISEASE;

EID: 0031820977     PISSN: 01418955     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005419122018     Document Type: Conference Paper

References (57)

1. Bradova V, Smid F, Ulrich-Bott B, et al (1993) Prosaposin deficiency: further characterization of the sphingolipid activator protein-deficient sibs. Multiple glycolipid elevations (including lactosylceramidosis), partial enzyme deficiencies and ultrastructure of the skin in this generalized sphingolipid storage disease. Hum Genet 92: 143-152.
2. Burkhardt JK, Hüttler S, Klein A, et al (1997) Accumulation of sphingolipids in SAP-precursor (prosaposin) deficient fibroblasts occurs as intralysosomal membrane structures and can be completely reversed by treatment with human SAP-precursor. Eur J Biochem 73: 10-18.
3. Christomanou H, Aignesberg A, Linke RP (1986) Immunochemical characterization of two activator proteins stimulating enzymic sphingomyelin degradation in vitro - absence of one of them in a human Gaucher disease variant. Biol Chem Hoppe-Seyler 367: 879-890.
4. Cohen-Tannoudji M, Marchand P, Akli S, et al (1995) Disruption of murine Hexa gene leads to enzymatic deficiency and to neuronal lysosomal storage, similar to that observed in Tay-Sachs disease. Mammalian Genome 6: 844-849.
5. Conzelmann E, Sandhoff K (1983/84) Partial enzyme deficiencies: residual activities and the development of neurological disorders. Dev Neurosci 6: 58-71.
6. Fujita N, Suzuki K, Vanier MT, et al (1996) Targeted disruption of the mouse sphingolipid activator protein gene: a complex phenotype, including severe leukodystrophy and wide-spread storage of multiple sphingolipids. Hum Mol Genet 5: 711-725.
7. Fukumoto S, Haraguchi M, Takeda N, et al (1996) Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. Proc Natl Acad Sci USA 93: 10662-10667.
8. Fürst W, Sandhoff K (1992) Activator proteins and topology of lysosomal sphingolipid catabolism. Biochim Biophys Acta 1126: 1-6.
9. Fürst W, Schubert J, Machleidt W, Meyer EH, Sandhoff K (1990) The complete amino-acid sequences of human ganglioside GM2 activator protein and cerebroside sulfate activator protein. Eur J Biochem 192: 709-714.
10. Gravel RA, Clarke JTR, Kaback MM, Mahuran D, Sandhoff K, Suzuki K (1995) The GM2 gangliosidoses. In Scriver C, Beaudet al Sly WS Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. McGraw-Hill: New York, 2839-2879.
11. Griffiths GW, Hoflack B, Simons K, Mellman IS, Kornfeld S (1988) The mannose-6-phosphate receptor and the biogenesis of lysosomes. Cell 52: 329-341.
12. Hahn CN, del Pilar M, Schröder M, et al (1997) Generalized CNS disease and massive G(M1)-ganglioside accumulation in mice defective in lysosomal acid beta-galactosidase. Hum Mol Genet 6: 205-211.
13. Hakomori S (1981) Glycosphingolipids in cellular interactions, differentiation and oncogenesis. Annu Rev Biochem 50: 733-764.
14. Harzer K, Paton BC, Poulos A (1989) Sphingolipid activator protein (SAP) deficiency in a 16-week old atypical Gaucher disease patient and his fetal sibling; biochemical signs of combined sphingolipidoses. Eur J Pediatr 149: 31-39.
15. Ho MW, O'Brien JS (1971) Gaucher's disease: deficiency of 'acid' β-glucosidase and reconstitution of enzyme activity in vitro. Proc Natl Acad Sci USA 68: 2810-2813.
16. Horinuchi K, Erlich S, Perl DP, et al (1995) Acid sphingomyelinase deficient mice: a new model for the study of types A and B Niemann-Pick disease. Nature Genet 10: 288-293.
17. Karlsson KA (1989) Animal glycosphingolipids as membrane attachment sites for bacteria. Annu Rev Biochem 58: 309-350.
18. Klima H, Klein A, van Echten G, Schwarzmann G, Suzuki K, Sandhoff K (1993) Over-expression of a functionally active human GM2-activator protein in Escherichia coli. Biochem J 292: 571-576.
19. Kobayashi T, Yamanaka T, Jacobs JM, et al (1980) The twitcher mouse: an enzymatically authentic model of human globoid cell leukodystrophy (Krabbe disease) Brain Res 202: 479-483.
20. Kolter T (1997) A chemical concept for the treatment of Tay-Sachs disease. Angew Chem Int Ed 36: 1955-1959.
21. Kolter T, Sandhoff K (1996) Inhibitors of glycosphingolipid biosynthesis. Chem Soc Rev 25: 371-381.
22. Kytzia HJ, Sandhoff K (1985) Evidence for two different active sites on human hexosaminidase - interaction of GM2 activator protein with hexosaminidase A. J Biol Chem 260: 7568-7572.
23. Leinekugel P, Michel S, Conzelmann E, Sandhoff K (1992) Quantitative correlation between the residual activity of β-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease. Hum Genet 88: 513-523.
24. Li S-C, Sonnino S., Tettamanti G., Li Y-T (1988) Characterization of a nonspecific activator protein for the enzymatic hydrolysis of glycolipids. J Biol Chem 263: 6588-6591.
25. Liu Y, Hoffmann A, Grinberg A, et al (1997) Mouse model of GM2 activator deficiency manifests cerebellar ganglioside storage and motor impairment. Proc Natl Acad Sci USA 94: 8138-8143.
26. Matsuda J, Suzuki O, Oshima A, et al (1997) Neurological manifestations of knockout mice with beta-galactosidase deficiency. Brain Dev 19: 19-20.
27. Matsushima GK, Taniike M, Glimcher LH, et al (1994) Absence of MHC class II molecules reduces CNS demyelination, microglial, macrophage infiltration and twitching in murine globoid cell leukodystrophy. Cell 78: 645-656.
28. Mehl E, Jatzkewitz H (1964) Eine Cerebrosidsulfatase aus Schweineniere. Hoppe-Seyler's Z Physiol Chem 339: 260-276.
29. Meier EM, Schwarzmann G, Fürst W, Sandhoff K (1991) The human GM2 activator protein: a substrate specific cofactor of hexosaminidase A. J Biol Chem 266: 1879-1887.
30. 3-Neu5Ac-gangliotriaosylsphingosine) in GM2 gangliosidosis brain. Biol Chem Hoppe-Seyler 367: 241-244.
31. Ohshima T, Murray GJ, Swaim WD, et al (1997) Alpha-galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci USA 94: 2540-2544.
32. Otterbach B, Stoffel W (1995) Acid sphingoyelinase-deficient mice mimic the neurovisceral form of human lysosomal storage disease (Niemann-Pick disease). Cell 81: 1053-1061.
33. Penzien JM, Kappler JM, Herschkowitz N, et al (1993) Compound heterozygosity for metachromatic leukodystrophy and arylsulfatase A pseudodeficiency alleles is not associated with progressive neurological disease. Am J Hum Genet 52: 557-564.
34. Phaneuf D, Wakamatsu N, Huang JQ, et al (1996) Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff disease. Hum Mol Genet 5: 1-14.
35. Platt FM, Neises GR, Karlsson GB, Dwek RA, Butters TD (1994) N-Butyldeoxynojirimycin inhibits glycolipid biosynthesis but does not affect N-linked oligosaccharide processing. J Biol Chem 269: 27108-27114.
36. Platt FM, Neises GR, Reinkensmeier G, et al (1997a). Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 276: 428-431.
37. Platt FM, Reinkensmeier G, Dwek RA, Butters TD (1997b) Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin. J Biol Chem 272: 19365-19372.
38. Purpura DP, Suzuki K (1976) Distortion of neuronal geometry and formation of aberrant synapses in neuronal storage disease. Brain Res 116: 1-21.
39. Sakai N, Inui K, Tatsumi N, et al (1996) Molecular cloning and expression of cDNA for murine galactocerebrosidase and mutation analysis of the twitcher mouse, a model of Krabbe's disease. J Neurochem 66: 1118-1124.
40. Sandhoff K, Kolter T (1995) Glykolipide der Zelloberfläche - Biochemie ihres Abbaus. Naturwissenschaften 82: 403-413.
41. Sandhoff K, Kolter T (1996) Topology of glycosphingolipid degradation. Trends Cell Biol 6: 98-103.
42. Sandhoff K, Harzer K, Fürst W (1995) Sphingolipid activator proteins. In: Scriver C, Beaudet al Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 7th edn. McGraw-hill, New York, 2427-2441.
43. Sango K, Yamanaka S, Hoffmann A, et al (1995) Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nature Genetics 11: 170-176.
44. Sango K, McDonald MP, Crawley JN et al (1996) Mice lacking both subunits of lysosomal beta-hexosaminidase display gangliosidosis and mucopolysaccharidosis. Nature Genetics 14: 348-352.
45. Schepers U, Glombitza GJ, Lemm T, et al (1997) Molecular analysis of a GM2-activator deficiency in two patients with GM2-gangliosidosis AB variant. Am J Hum Genet 59: 1048-1056.
46. Schnaar RL (1991) Glycosphingolipids in cell surface recognition. Glycobiology 1: 477-485.
47. Schnabel D, Schröder M, Sandhoff K (1991) Mutation in the sphingolipid activator protein 2 in a patient with a variant of Gaucher disease. FEBS Lett 284: 57-59.
48. Schnabel D, Schröder M, Fürst W, et al (1992) Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene. J Biol Chem 267: 3312-3315.
49. Spiegel S, Foster D, Kolesnick R (1996) Signal transduction through lipid second messengers. Curr Opin Cell Biol 8: 159-167.
50. Taniike M, Yamanaka S, Proia RL, Langaman C, Bonc-Turentine T, Suzuki K (1995) Neuropathology of mice with targeted disruption of Hexa gene, a model of Tay-Sachs disease. Acta Neuropathol 89: 296-304.
51. Tybulewicz VLJ, Tremblay ML, LaMarca ME, et al (1992) Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene. Nature 357: 407-410.
52. van Echten G, Sandhoff K (1993) Ganglioside metabolism. J Biol Chem 268: 5341-5344.
53. van Helvoort A, van Meer G (1995) Intracellular lipid heterogeneity caused by topology of synthesis and specificity in transport. Example: sphingolipids. FEBS Lett 369: 18-21.
54. Wiegandt H (1985) Gangliosides. In Neuberger A, van Deenen LLM, eds. New Comprehensive Biochemistry, vol. 10. Amsterdam: Elsevier, 199-260.
55. Yamanaka S, Johnson MD, Grinberg A, et al (1994) Targeted disruption of the Hexa gene results in mice with biochemical and pathologic features of Tay-Sachs disease. Proc Natl Acad Sci USA 91: 9975-9979.
56. Zeller CB, Marchase RB (1992) Gangliosides as modulators of cell function. Am J Physiol 262: C1341-C1355.
57. Zhou XY, Morreau H, Rottier R, et al (1995) Mouse model for the lysosomal disorder galactosialidosis and correction of the phenotype with over-expressing erythroid precursor cells. Genes Dev 9: 2623-2634.